Interestingly, a 3-day injection protocol of CNO effectively reduced T1D hyperglycemia in Vgat-Cre mice, but had no effects on either AgRP-Cre mice or “missed-targeted” mice (Fig. 3d). Here, SLC32A1 is linked to Hyperglycemia.